Camp Robert L, Neumeister Veronique, Rimm David L
Department of Pathology, Yale University School of Medicine, 310 Cedar St, PO Box 208023, New Haven, CT 06520-8023, USA.
J Clin Oncol. 2008 Dec 1;26(34):5630-7. doi: 10.1200/JCO.2008.17.3567. Epub 2008 Oct 20.
This year, 2008, marks the 10-year anniversary of the development of the modern tissue microarray (TMA). During the last decade, the use of TMAs has grown steadily and accounts for a small but increasing percentage of all cancer biomarker studies performed. The growing popularity of TMA-based studies attests to their benefits in the discovery and validation of new biomarkers. This review will focus on these benefits, but also on the faults of TMAs and the challenges of TMA studies that have been overcome in the last decade. We will also discuss the role of TMAs in the latest revolution in cancer treatment, the use of targeted drug therapy.
2008年是现代组织微阵列(TMA)技术问世10周年。在过去十年中,TMA的应用稳步增长,在所有癌症生物标志物研究中所占比例虽小但呈上升趋势。基于TMA的研究越来越受欢迎,证明了其在发现和验证新生物标志物方面的优势。本综述将聚焦于这些优势,同时也会探讨TMA的缺点以及过去十年中已克服的TMA研究面临的挑战。我们还将讨论TMA在癌症治疗最新革命——靶向药物治疗中的作用。